Stability of Murine Monoclonal Anti-A, Anti-B and Anti-A,B
ABO Grouping Reagents and A Multi-Centre Evaluation of
Their Performance in Routine Use

McGowan, A.; Tod, Anne; Chirnside, Ann; Green, C.; McColl, K.; Moore, S.; Yap, P.L.; McClelland, D.B.L.; McCann, Moira; Micklem, L.R.; James, K.

doi:10.1159/000460942

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worthwhile to recall a number of practical immunohematology discoveries and their application to a standard of practice (Table 1). 108‐117 We realize that there are often lengthy timelines from their discovery and application in innovative laboratories to their recognition as standards of practice.…”

Section: Timelines From Immunohematology Discoveries To Their Applicamentioning

confidence: 99%

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Denomme

Flegel

2008

Transfusion

View full text Add to dashboard Cite

Lessons from more than 100 years of immunohematology exemplify that many critical discoveries were made serendipitously and their more rapid implementation could have benefited transfusion recipients and pregnancies. Constituents of blood that are not essential for the attempted therapeutic benefit of a transfusion are largely removed from today's blood products. We are now moving on to avoid unnecessary exposure to potentially harmful constituents of the therapeutically required cells, like blood group antigens that are foreign to the patient. Cost efficacy needs to be kept in mind but may eventually prove much better than anticipated, once hidden benefits are captured, as we show by examples from past immunohematologic developments. Here, we detail clinical applications for molecular immunohematology advances including "dry-matching" that will improve transfusion outcomes and argue for their widespread implementation by rapid timelines through standards of practice.

show abstract

Section: Timelines From Immunohematology Discoveries To Their Applicamentioning

confidence: 99%

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Denomme

Flegel

2008

Transfusion

View full text Add to dashboard Cite

show abstract

“…For blood grouping purposes, monoclonal antibodies are preferable to plasma from immunized individuals since their in vitro production allows for theoretically unlimited supplies of consistent reagents. Although murine monoclonal antibodies have been produced against some blood group antigens such as A and B [3,4], the production of murine antibodies against Rh antigens has not been satisfactorily achieved. However, the production of human monoclonal antibodies against the major Rh antigens D, C, c, E and e for use as grouping reagents has been reported by several groups [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Immunochemical Characterization of the Rh C^w Antigen Using Human Monoclonal Antibodies

Thorpe¹,

Boult²,

Thompson³

1997

Vox Sanguinis

View full text Add to dashboard Cite

Background and objectives: Human monoclonal antibodies have been produced against various Rh antigens. We report here the production of another one against Rh C^w and the first such antibody against Rh C^w. Materials and methods: Two heterohybridomas secreting lgG human monoclonal antibodies against Rh C^w and Rh C (MS-353 and MS-242 respectively) were produced from alloimmunized donors. Their specificity was confirmed by serological testing. Results: MS-353 reacted with all C^w -positive phenotypes but not with any Cwnegative phenotypes, whereas MS-242 reacted with all C^w-positive and C-positive phenotypes. Using ^125 -labelled antibodies, the average number of C^w sites/ red cell was 32,000 (R(1)^w R(1)^w), 15,200 (R(1) ^w R(2)), 19,800 (R(1)^W R(2)), 15,300 (R(1) ^wr), 26,200 (r ^w r), and the average number of C sites per red cell on equivalent C^w/Cpositive phenotypes was similar: 22,400 (R(1) R(1)), 21,800 (R(1) ^w R,), 12,300 (R(1) R(2)), 11,700 (R(1) ^wR(2), 13,400 (R,r), 15,100 (R(1) ^wr), 21,100 (r'r), 18,700 (r ^wr). MS-353 and MS-242 were mutually inhibitory. Both antibodies specifically immunoprecipitated a 33- to 34-kD polypeptide from l2:T-surface-labelled cells. Conclusion: MS-353 is suitable for the serological detection of C^w -positive cells, and the immunochemical data are entirely consistent with the report that the C^w antigen is associated with a point mutation in the RHCE gene [Blood, 1995;86:1196 1201],

show abstract

Predictive modeling of complex ABO glycan phenotypes by lectin microarrays

Anani

Ashwood²,

Schmidt³

et al. 2020

Blood Advances

View full text Add to dashboard Cite

Serological classification of individuals as A, B, O, or AB is a mainstay of blood banking. ABO blood groups or ABH antigens, in addition to other surface glycans, act as unique red blood cell (RBC) signatures and direct immune responses. ABO subgroups present as weakened, mixed field, or unexpected reactivity with serological reagents, but specific designations remain complex. Lectins detect glycan motifs with some recognizing ABH antigens. We evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, n = 20 for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology. Principal component analysis highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods. Transfusion services observe alterations in ABH expression during malignancy, and ABO incompatible solid organ transplantation is not without risk of rejection. The presented methods may identify subtle but clinically significant ABO blood group differences for transfusion and transplantation.

show abstract

Stability of Murine Monoclonal Anti-A, Anti-B and Anti-A,B ABO Grouping Reagents and A Multi-Centre Evaluation of Their Performance in Routine Use

Cited by 4 publications

References 5 publications

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Immunochemical Characterization of the Rh C^w Antigen Using Human Monoclonal Antibodies

Predictive modeling of complex ABO glycan phenotypes by lectin microarrays

Contact Info

Product

Resources

About